• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国成年人他汀类药物使用情况及低密度脂蛋白胆固醇水平的趋势:2001年国家胆固醇教育计划指南的影响

Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.

作者信息

Mann Devin, Reynolds Kristi, Smith Donald, Muntner Paul

机构信息

Mount Sinai School of Medicine, New York, NY 10029, USA.

出版信息

Ann Pharmacother. 2008 Sep;42(9):1208-15. doi: 10.1345/aph.1L181. Epub 2008 Jul 22.

DOI:10.1345/aph.1L181
PMID:18648016
Abstract

BACKGROUND

Few data are available on the use of statins after publication of the National Cholesterol Education Program Third Adult Treatment Panel (ATP-III) guidelines in 2001.

OBJECTIVE

To determine changes in statin use and its impact on low-density lipoprotein cholesterol (LDL-C) control among US adults from 1999 to 2004.

METHODS

High LDL-C levels and statin use among 1911 participants of the National Health and Nutrition Examination Survey (NHANES) 2003-2004 were determined and compared with 1770 and 2094 participants of NHANES 1999-2000 and NHANES 2001-2002, respectively. Statin use was obtained from review of participants' drug containers. High LDL-C levels and LDL-C control were defined, using risk-specific cut-points from the ATP-III guidelines.

RESULTS

Statins were taken by 24 million Americans in 2003-2004, an increase from 12.5 million in 1999-2000. In 1999-2000, 2001-2002, and 2003-2004, statins were being used by 19.6%, 27.3%, and 35.9% of US adults with high LDL-C levels, respectively (p trend <0.001). Age-standardized mean LDL-C declined from 119.9 to 112.0 to 100.7 mg/dL among statin users between 1999-2000, 2001-2002, and 2003-2004. LDL-C control to ATP-III recommended targets was achieved by 49.7%, 67.4%, and 77.6% of statin users in 1999-2000, 2001-2002, and 2003-2004, respectively (p trend <0.001). Among US adults with high LDL-C, after multivariate adjustment, non-Hispanic blacks were 39% less likely (prevalence ratio = 0.61; 95 CI 0.39 to 0.97) than non-Hispanic whites to be taking statins.

CONCLUSIONS

Statin use continues to increase among US adults and this has led to substantial improvements in LDL-C control. Nevertheless, suboptimal statin use, especially among racial/ethnic minorities, continues to prevent the maximal public health benefit from this effective drug class.

摘要

背景

2001年美国国家胆固醇教育计划第三次成人治疗专家组(ATP-III)指南发布后,关于他汀类药物使用的数据较少。

目的

确定1999年至2004年美国成年人中他汀类药物使用情况的变化及其对低密度脂蛋白胆固醇(LDL-C)控制的影响。

方法

确定了2003 - 2004年美国国家健康与营养检查调查(NHANES)1911名参与者的高LDL-C水平和他汀类药物使用情况,并分别与1999 - 2000年NHANES的1770名参与者和2001 - 2002年NHANES的2094名参与者进行比较。他汀类药物的使用情况通过检查参与者的药盒获得。根据ATP-III指南中特定风险的切点定义高LDL-C水平和LDL-C控制情况。

结果

2003 - 2004年有2400万美国人服用他汀类药物,高于1999 - 2000年的1250万。在1999 - 2000年、2001 - 2002年和2003 - 2004年,LDL-C水平高的美国成年人中分别有19.6%、27.3%和35.9%使用他汀类药物(p趋势<0.001)。在1999 - 2000年、2001 - 2002年和2003 - 2004年期间,他汀类药物使用者的年龄标准化平均LDL-C水平分别从119.9降至112.0再降至100.7mg/dL。1999 - 2000年、2001 - 2002年和2003 - 2004年分别有49.7%、67.4%和77.6%的他汀类药物使用者将LDL-C控制在ATP-III推荐的目标水平(p趋势<0.001)。在美国LDL-C水平高的成年人中,经过多变量调整后,非西班牙裔黑人服用他汀类药物的可能性比非西班牙裔白人低39%(患病率比=0.61;95%置信区间0.39至0.97)。

结论

美国成年人中他汀类药物的使用持续增加,这已使LDL-C控制有了显著改善。然而,他汀类药物使用不充分,尤其是在少数种族/族裔中,继续阻碍了这类有效药物实现最大的公共卫生效益。

相似文献

1
Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.美国成年人他汀类药物使用情况及低密度脂蛋白胆固醇水平的趋势:2001年国家胆固醇教育计划指南的影响
Ann Pharmacother. 2008 Sep;42(9):1208-15. doi: 10.1345/aph.1L181. Epub 2008 Jul 22.
2
Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults.美国成年人中符合ATP-III定义的高胆固醇血症患病率、知晓率、治疗率及控制率的趋势。
Ann Epidemiol. 2007 Jul;17(7):548-55. doi: 10.1016/j.annepidem.2007.01.032. Epub 2007 Mar 28.
3
Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.直接面向消费者的羟甲基戊二酰辅酶A还原酶抑制剂广告对低密度脂蛋白胆固醇(LDL-C)目标达成情况的影响。
Clin Ther. 2006 Dec;28(12):2105-18; discussion 2104. doi: 10.1016/j.clinthera.2006.12.015.
4
Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.在常规护理环境中,瑞舒伐他汀与其他他汀类药物相比对血脂水平及达到国家胆固醇教育计划低密度脂蛋白胆固醇目标的影响。
Pharmacotherapy. 2006 Apr;26(4):469-78. doi: 10.1592/phco.26.4.469.
5
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗专家组第三次指南的影响。
Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. doi: 10.1161/01.ATV.0000133317.49796.0E.
6
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.近期临床试验对美国国家胆固醇教育计划成人治疗专家组第三次指南的影响。
J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001.
7
Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.与其他他汀类药物相比,瑞舒伐他汀降低糖尿病患者低密度脂蛋白胆固醇的有效性及达到美国国家胆固醇教育计划成人治疗小组第三次指南低密度脂蛋白胆固醇目标的情况:一项使用美国电子病历数据集的回顾性研究
Curr Med Res Opin. 2007 Sep;23(9):2125-33. doi: 10.1185/030079907X219580.
8
Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004.美国有和没有心血管合并症的成年人血脂异常的患病率、程度及推荐的血脂水平:2003 - 2004年国家健康和营养检查调查
Am Heart J. 2008 Jul;156(1):112-9. doi: 10.1016/j.ahj.2008.03.005. Epub 2008 May 15.
9
Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.以高密度脂蛋白胆固醇水平低为特征的人群中血脂异常的风险判定
Am Heart J. 2003 Dec;146(6):1052-9. doi: 10.1016/S0002-8703(03)00516-7.
10
Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.美国心脏风险和低密度脂蛋白胆固醇分布对血脂异常诊断和治疗的影响:来自1999年至2002年国家健康和营养检查调查的数据
Circulation. 2007 Mar 20;115(11):1363-70. doi: 10.1161/CIRCULATIONAHA.106.645473. Epub 2007 Mar 12.

引用本文的文献

1
Duration and type of statin use and long-term risk of type 2 diabetes among men and women with hypercholesterolaemia: findings from three prospective cohorts.高胆固醇血症男性和女性使用他汀类药物的持续时间、类型与2型糖尿病的长期风险:三项前瞻性队列研究的结果
Diabetologia. 2025 May 2. doi: 10.1007/s00125-025-06441-3.
2
Sex-based utilization of guideline recommended statin therapy and cardiovascular disease outcomes: Data from a multisite healthcare network primary prevention cohort.基于性别的指南推荐他汀类药物治疗的使用情况及心血管疾病结局:来自多站点医疗保健网络一级预防队列的数据。
Am J Prev Cardiol. 2024 May 9;18:100667. doi: 10.1016/j.ajpc.2024.100667. eCollection 2024 Jun.
3
Sociodemographic Disparities in Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Prescription Patterns Among Patients With Poorly Controlled Diabetes.
血糖控制不佳的糖尿病患者中钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂处方模式的社会人口学差异
Cureus. 2024 Mar 24;16(3):e56845. doi: 10.7759/cureus.56845. eCollection 2024 Mar.
4
Racial differences in low value care among older adult Medicare patients in US health systems: retrospective cohort study.美国医疗体系中老年 Medicare 患者的低价值护理中的种族差异:回顾性队列研究。
BMJ. 2023 Oct 25;383:e074908. doi: 10.1136/bmj-2023-074908.
5
Rarely tested or treated but highly prevalent: Hypercholesterolemia in ED observation unit patients with chest pain.罕见的检测或治疗但高度普遍:胸痛 ED 观察单元患者的高胆固醇血症。
Am J Emerg Med. 2023 Sep;71:47-53. doi: 10.1016/j.ajem.2023.06.009. Epub 2023 Jun 10.
6
More Treatment, but Not Less Anxiety and Mood Disorders: Why? Seven Hypotheses and Their Evaluation.更多治疗,却未能减少焦虑和情绪障碍:为何?七个假设及其评估。
Psychother Psychosom. 2023;92(2):73-80. doi: 10.1159/000528544. Epub 2023 Feb 6.
7
Leveraging Healthcare System Data to Identify High-Risk Dyslipidemia Patients.利用医疗保健系统数据识别高危血脂异常患者。
Curr Cardiol Rep. 2022 Oct;24(10):1387-1396. doi: 10.1007/s11886-022-01767-5. Epub 2022 Aug 22.
8
Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.他汀类药物与胃癌患者生存改善相关:系统评价和荟萃分析。
Int J Clin Pract. 2022 May 17;2022:4938539. doi: 10.1155/2022/4938539. eCollection 2022.
9
Race and Sex Differences in Mortality in Individuals with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者的死亡率存在种族和性别差异。
Ann Am Thorac Soc. 2022 Oct;19(10):1661-1668. doi: 10.1513/AnnalsATS.202112-1346OC.
10
Gaps and Disparities in Primary Prevention Statin Prescription During Outpatient Care.初级预防他汀类药物处方在门诊护理中的差距和差异。
Am J Cardiol. 2021 Dec 15;161:36-41. doi: 10.1016/j.amjcard.2021.08.070.